What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To develop and evaluate fully human anti-CD38 CAR-γδ T cells for treating myeloma patients.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

In vitro and in vivo assays show cytotoxicity of fully human anti-CD38 CAR-γδ T cells in myeloma, indicating potential for off-the-shelf therapy.

To develop and evaluate fully human anti-CD38 CAR-γδ T cells for treating myeloma patients.
Cultured γδ T cells using zoledronic acid and IL-2 from PBMCs of healthy donors.
Developed a retroviral construct with a fully human scFv anti-CD38 gene.
Assessed transduction efficiency and CD38 expression using flow cytometry.
Conducted in vitro co-culture experiments with myeloma cell lines and fresh patient cells.
Performed in vivo studies on NOG mice with luciferase-transfected KMM1 cells.
Achieved over 90% transduction efficiency of anti-CD38 gene in γδ T cells.
Demonstrated efficient cytotoxic activity against myeloma cells in vitro, showing over 90% efficacy at specific E:T ratios.
Inhibited myeloma growth in vivo in xenograft models up to day 28.

Hattori et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

In vitro and in vivo assays show cytotoxicity of fully human anti-CD38 CAR-γδ T cells in myeloma, indicating potential for off-the-shelf therapy.

To develop and evaluate fully human anti-CD38 CAR-γδ T cells for treating myeloma patients.
Cultured γδ T cells using zoledronic acid and IL-2 from PBMCs of healthy donors.
Developed a retroviral construct with a fully human scFv anti-CD38 gene.
Assessed transduction efficiency and CD38 expression using flow cytometry.
Conducted in vitro co-culture experiments with myeloma cell lines and fresh patient cells.
Performed in vivo studies on NOG mice with luciferase-transfected KMM1 cells.
Achieved over 90% transduction efficiency of anti-CD38 gene in γδ T cells.
Demonstrated efficient cytotoxic activity against myeloma cells in vitro, showing over 90% efficacy at specific E:T ratios.
Inhibited myeloma growth in vivo in xenograft models up to day 28.

Hattori et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark